1 completed, 1 terminated. 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Immune Complex Membranoproliferative Glomerulonephritis: new trials by email Literature Review of Immune Complex Membranoproliferative Glomerulonephritis trials Research Report on Immune Complex Membranoproliferative Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study Non contrast-enhanced magnetic resonance imaging - C3 Glomerulonephritis, C3 Glomerulopathy | Not applicable | Completed | Mario Negri Institute for Pharmacological Research | 7 | 2018-12-06 | 2021-11-26 |
| A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 Danicopan - C3 Glomerulonephritis, C3 Glomerulopathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 22 | 2018-06-20 | 2023-08-21 |
Glomerulonephritis, Membranoproliferative (2)
Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Glomerulonephritis (2) · Immune System Diseases (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Nephritis (2) · Urogenital Diseases (2) · Urologic Diseases (2)
danicopan (1)
Alexion Pharmaceuticals, Inc. (1) · Mario Negri Institute for Pharmacological Research (1)
Italy (2) · Australia (1) · Belgium (1) · Netherlands (1) · United States (1)
2017 (1)